Recruitment status
- Recruiting7
- Completed4
- Active, not recruiting3
- Withdrawn3
- Not yet recruiting1
- Unknown status1
Psilocybin-Research.comSearchable psilocybin and psilocin bibliometric database.
Anxiety trial landscape
Psilocybin Clinical Trials for Anxiety
Review registry-listed psilocybin studies whose condition fields explicitly include anxiety, with current status, phase, enrollment, sites, and source links.
Registry status is not a guarantee of local availability, eligibility, safety, or efficacy. Confirm every participation decision in the authoritative ClinicalTrials.gov record.
19matching trials
7currently recruiting
21registry-listed sites
Registry facts checkedAug 10, 2026 01:26 UTC
Live registry synthesis
Status, geography, and study phase
Anxiety can be a primary condition or part of a broader clinical context. This collection preserves the registered condition labels so users can distinguish populations and protocols.
Leading countries
- United States10
- Switzerland3
- Canada2
- Jamaica1
Trial phases
- Phase 216
- Phase 13
- Early Phase 11
Server-rendered source index
19 matching registry records
Every factual summary is crawlable without JavaScript. Use the direct registry link for current eligibility, contacts, and site availability.
Active, not recruitingNCT07336238
A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression
University of Washington
- Conditions
- Anxiety · Depression · Hematopoietic and Lymphatic System Neoplasm · Metastatic Malignant Solid Neoplasm
- Phase
- Phase 2
- Enrollment
- 18 estimated
- Locations
- Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
- Registry updated
- 2026-07-31
RecruitingNCT06200155
TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
M.D. Anderson Cancer Center
- Conditions
- Depression, Anxiety · Psilocybin-Assisted Psychotherapy · Advanced Cancer
- Phase
- Phase 2
- Enrollment
- 30 estimated
- Locations
- MD Anderson Cancer Center, Houston, Texas, United States
- Registry updated
- 2026-07-29
RecruitingNCT06801041
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
M.D. Anderson Cancer Center
- Conditions
- Depression · Anxiety · Cancer
- Phase
- Phase 2
- Enrollment
- 20 estimated
- Locations
- The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
- Registry updated
- 2026-07-29
RecruitingNCT06820723
A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety
Ohio State University
- Conditions
- Depression · Anxiety · Major Depressive Disorder
- Phase
- Phase 2
- Enrollment
- 40 estimated
- Locations
- The Ohio State University Department of Psychiatry, Columbus, Ohio, United States
- Registry updated
- 2026-07-23
Active, not recruitingNCT04754061
PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial
Ottawa Hospital Research Institute
- Conditions
- Depression, Anxiety · Distress, Emotional
- Phase
- Phase 1 · Phase 2
- Enrollment
- 20 estimated
- Locations
- The Ottawa Hospital, Ottawa, Ontario, Canada · Bruyere Continuing Care, Ottawa, Ontario, Canada
- Registry updated
- 2026-07-10
Not yet recruitingNCT07565909
A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression
University of Washington
- Conditions
- Depression · Anxiety
- Phase
- Phase 2
- Enrollment
- 72 estimated
- Locations
- No mapped site reported
- Registry updated
- 2026-05-04
RecruitingNCT05883540
Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)
University Hospital, Basel, Switzerland
- Conditions
- Palliative Care · Pain · Anxiety · Depression
- Phase
- Phase 2
- Enrollment
- 60 estimated
- Locations
- University Hospital Basel, Division of Clinical Pharmacology and Toxicology, Basel, Switzerland · University Hospital Geneva, Palliative medicine department, Collonge-Bellerive, Switzerland · Spital Uster AG, Division of Internal Medicine, Uster, Switzerland · +1 more
- Registry updated
- 2026-04-29
RecruitingNCT06442423
Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study
Yale University
- Conditions
- Transdiagnostic · Depression - Major Depressive Disorder · Anxiety · PTSD Symptoms
- Phase
- Phase 1
- Enrollment
- 50 estimated
- Locations
- Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut, United States
- Registry updated
- 2026-03-11
Active, not recruitingNCT07164287
Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment
University Hospital, Geneva
- Conditions
- Major Depressive Disorder (MDD) · Anxiety Disorders · Substance Use Disorder (SUD) · PTSD - Post Traumatic Stress Disorder
- Phase
- Phase not reported
- Enrollment
- 376 estimated
- Locations
- Geneva University Hospital, Geneva, Switzerland
- Registry updated
- 2025-10-02
RecruitingNCT06899165
Processing Intergenerational Trauma With Psilocybin-Assisted Therapy
Rachel Yehuda
- Conditions
- Psychological Stress · Depression · Anxiety
- Phase
- Phase 2
- Enrollment
- 100 estimated
- Locations
- The Parsons Research Center for Psychedelic Healing, New York, New York, United States
- Registry updated
- 2025-09-08
RecruitingNCT06969170
A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder
Queen's University
- Conditions
- Generalized Anxiety Disorder (GAD)
- Phase
- Phase 2
- Enrollment
- 50 estimated
- Locations
- Kingston General Health Research Institute, Kingston, Ontario, Canada
- Registry updated
- 2025-05-13
CompletedNCT00302744
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Conditions
- Anxiety
- Phase
- Phase 1 · Phase 2
- Enrollment
- 12 actual
- Locations
- Harbor-UCLA Medical Center, Torrance, California, United States
- Registry updated
- 2025-03-13
CompletedNCT04932434
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study
Joshua Woolley, MD, PhD
- Conditions
- Parkinson Disease · Depression · Anxiety
- Phase
- Phase 2
- Enrollment
- 12 actual
- Locations
- University of California, San Francisco, San Francisco, California, United States
- Registry updated
- 2025-01-01
Unknown statusNCT06444243
A Multi-centre, Double-blinded, Placebo-controlled, Randomised, Phase II Clinical Trial for Psilocybin-assisted Therapy for Alcohol Use Disorder
University of Sydney
- Conditions
- Alcohol Use Disorder · Alcohol Dependence · Depression · Anxiety
- Phase
- Phase 2
- Enrollment
- 90 estimated
- Locations
- No mapped site reported
- Registry updated
- 2024-06-10
WithdrawnNCT00979693
Psilocybin-assisted Psychotherapy in the Management of Anxiety Associated With Stage IV Melanoma.
Multidisciplinary Association for Psychedelic Studies
- Conditions
- Anxiety · Stage IV Melanoma
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States
- Registry updated
- 2023-12-26
WithdrawnNCT05252598
Mood and Cognitive Effects of Low Doses of Psilocybin Observed in Healthy Subjects ("MELO"): A Blinded, Placebo-Controlled, Dose-Finding Study
Optimi Health Corporation
- Conditions
- Mood Disturbance · Mood Change · Sleep Disturbance · Drug Effect
- Phase
- Early Phase 1
- Enrollment
- 0 actual
- Locations
- No mapped site reported
- Registry updated
- 2023-03-20
WithdrawnNCT04989972
Randomized Double Blind Placebo Controlled Assessing the Efficacy of Micro-dosed Psilocybin in Reducing Anxiety and or Depression Levels in Adults
Wake Network, Inc.
- Conditions
- Anxiety and Depression
- Phase
- Phase 2
- Enrollment
- 0 actual
- Locations
- FMS Department of Psychiatry, Kingston, Jamaica
- Registry updated
- 2022-06-30
CompletedNCT03153579
LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders: a Randomized, Double-blind, Placebo-controlled Phase II Study
University Hospital, Basel, Switzerland
- Conditions
- Patients · Anxiety Disorders
- Phase
- Phase 2
- Enrollment
- 46 actual
- Locations
- University Hospital Basel, Basel, Canton of Basel-City, Switzerland · Private Practice P.Gasser, Solothurn, Canton of Solothurn, Switzerland
- Registry updated
- 2021-12-22
CompletedNCT00465595
Psychopharmacology of Psilocybin in Cancer Patients
Johns Hopkins University
- Conditions
- Depressive Symptoms · Anxiety · Cancer
- Phase
- Phase 2
- Enrollment
- 56 actual
- Locations
- Behavioral Pharmacology Research Unit, Johns Hopkins Bayview Campus, Baltimore, Maryland, United States
- Registry updated
- 2018-07-19
Related research views
Continue exploring clinical trials
Move between curated condition, country, phase, and recruiting views without losing direct source provenance.
Recruitment
Conditions
Countries
Phases
Method and accountability
How this collection is maintained
Automatic refresh: counts, facets, records, and the map update from the tracker after scheduled ClinicalTrials.gov refreshes. The registry remains authoritative.
Rights-safe scope: the page exposes allowlisted factual metadata. Registry descriptions, contacts, raw payloads, and source-derived keywords are not redistributed.
Editorial review: collection definitions, limitations, corrections, and authorship are documented in the editorial and methodology policy.